Gene · 7334
UBE2N: ubiquitin conjugating enzyme E2 N
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. UBE2N: ubiquitin conjugating enzyme E2 N. Genes, record 7334. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/7334
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P61088 | Ubiquitin-conjugating enzyme E2 N | 152 | 44 | Ensembl, GeneID, HGNC |
Source UniProt
Patents58
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 5053 | P61088 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5053 | P61088 | Espacenet |
| US 11976334 B2 | 2024-05-07 | 212 | P61088 | Espacenet |
| JP 2023550743 A | 2023-12-05 | 88 | P61088 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5398 | P61088 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 95253 | P61088 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 198224 | P61088 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 12239 | P61088 | Espacenet |
| JP 2020508335 A | 2020-03-19 | 212 | P61088 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 2730 | P61088 | Espacenet |
1 to 10 of 58
See all 58 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,718
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | UBE2N papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 17 | 2025 |
| R01GM065334 | Solution structure and dynamics of polyubiquitin chains | 10 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 8 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| R01AI127465 | Effector-mediated ubiquitin manipulation in Legionella pneumophila pathogenesis | 6 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 4 | 2025 |
| P30CA054174 | Mays Cancer Center at UT Health SA | 4 | 2025 |
1 to 10 of 1,718Source NIH's project files
See all 1,718 nih grantsPapers2,223
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MCPH1 and DNA Damage Response Pathway Genes as Candidate Susceptibility Loci in Hereditary Breast Cancer. | Diagnostics (Basel) | 2026 | 42793752 | PubTator, text mining | PubMed |
| Fluorophore placement and size impact E2 ubiquitination efficiency. | Biochem J | 2026 | 42770861 | PubTator, text mining | PubMed |
| UBE2N flips the switch on for mitophagy and off for MASH. | Nat Metab | 2026 | 42698002 | PubTator, text mining | PubMed |
| UBE2N deficiency contributes to MASH development via p62-regulated mitophagy and PANoptosis. | Nat Metab | 2026 | 42698001 | PubTator, text mining | PubMed |
| Small-molecule disruption of the TRAF6-Ubc13 protein-protein interaction: targeting noncanonical ubiquitin signaling in inflammation and cancer. | Biochem Pharmacol | 2026 | 42660298 | PubTator, text mining | PubMed |
| Inhibition of UBE2N enhances TRAIL-mediated apoptosis through upregulation of DR5 in cancer cells. | Int J Med Sci | 2026 | 42524317 | PubTator, text mining | PubMed |
| Ubiquitin-Derived Diglycine Remnants as Chemical Handles for Chemoenzymatic Proteomics. | bioRxiv | 2026 | 42427753 | PubTator, text mining | PubMed |
| Discovery of hub genes linking oxidative stress to type 2 diabetic sarcopenia using single-cell sequencing and machine learning. | PLoS One | 2026 | 42412755 | PubTator, text mining | PubMed |
| BRD4-mediated histone H4K12 lactylation drives ovarian cancer progression by activating the Ube2v1-DDX3X ubiquitination axis. | J Transl Med | 2026 | 42374413 | PubTator, text mining | PubMed |
| Proteomics in myelodysplastic syndromes: towards novel prognostic and diagnostic biomarkers. | Biochem Med (Zagreb) | 2026 | 42299353 | PubTator, text mining | PubMed |
1 to 10 of 2,223
See all 2,223 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/7334
GET https://conductscience.org/api/genes/v1/7334/patents?page=2